Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL), a highly heterogeneous B-cell malignancy, is characterized by tumor microenvironment disorder and T-cell immune dysfunction, which play a major role in the proliferation and survival of CLL cells. Ibrutinib is the first irreversible inhibitor of Bruton’s tyrosine...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yanyan, Song, Yongping, Yin, Qingsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437578/
https://www.ncbi.nlm.nih.gov/pubmed/36059445
http://dx.doi.org/10.3389/fimmu.2022.962552

Ejemplares similares

Ejemplares similares